xml version="1.0" encoding="utf-8"?              

   0000064803 false        0000064803   2020-02-03 2020-02-03    iso4217:USD   xbrli:shares     iso4217:USD   xbrli:shares       

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 

 Date of Report (Date of earliest event reported):  February 3, 2020  

CVS HEALTH CORPORATION 

(Exact name of registrant as specified in its charter) [DATA_TABLE_REMOVED] 

  [DATA_TABLE_REMOVED] 

Registrant’s telephone number, including area code: (401) 765-1500 

Former name or former address, if changed since last report: N/A 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act: [DATA_TABLE_REMOVED] 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

 Emerging growth company o 

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o  

Section 5 – Corporate Governance and Management 

 Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 

(b) To the extent applicable, the information in the below Item 8.01 is incorporated by reference herein. 

Section 8 – Other Events 

 Item 8.01.Other Events. 

CVS Health Corporation (“CVS Health”) today announced upcoming changes to its Board of Directors (the “Board”). Richard “Dick” Swift, Richard Bracken and Mark Bertolini will not stand for re-election at CVS Health’s upcoming Annual Meeting of Stockholders (the “Annual Meeting”). Following the Annual Meeting, the Board will then be reduced to 13 from 16 directors, in order to further align with corporate governance best practices. 

A copy of the press release dated February 3, 2020 is attached hereto as Exhibit 99.1 and incorporated by reference herein. 

Section 9 – Financial Statements and Exhibits 

 Item 9.01Financial Statements and Exhibits. 

(d) Exhibits. 

The exhibits to this Current Report on Form 8-K are as follows: 

INDEX TO EXHIBITS 

99.1 Press Release of CVS Health Corporation dated February 3, 2020 

104 Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document). 

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

  [DATA_TABLE_REMOVED]